Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
|HIV Infections||Drug: Emtricitabine/tenofovir disoproxil fumarate Drug: Placebo||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Prevention
|Official Title:||Chemoprophylaxis for HIV Prevention in Men|
- Anti-HIV seroconversion [ Time Frame: At 36 months ]
- Safety endpoints, including Grade 1 or higher creatinine toxicity; Grade 3 or higher phosphorous toxicity; Grade 2, 3, or 4 laboratory adverse events; or Grade 2, 3, or 4 clinical adverse events; or HIV seroconversion [ Time Frame: Throughout study ]
- Hepatitis flares among hepatitis B virus (HBV) infected persons during and after chemoprophylaxis [ Time Frame: At 42 months ]
- Changes in bone mineral density, body fat distribution, or fasting triglyceride and cholesterol levels [ Time Frame: At 42 months ]
- Among HIV infected participants: viral load, drug resistance, and CD4 count [ Time Frame: At 42 months ]
- Proportion of missed doses by pill count and by estimate during CASI interview [ Time Frame: At 36 months ]
- Risk behavior, including number of sexual partners with HIV positive or unknown status, total number of sexual partners, and condom use before, during, and after use of study medication [ Time Frame: At 42 months ]
- Prevalence of sexually transmitted infections (STIs) before, during, and after use of study medication [ Time Frame: At 42 months ]
|Study Start Date:||June 2007|
|Study Completion Date:||February 2014|
|Primary Completion Date:||February 2014 (Final data collection date for primary outcome measure)|
Daily oral emtricitabine/tenofovir disoproxil fumarate
Drug: Emtricitabine/tenofovir disoproxil fumarate
Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
Placebo Comparator: 2
Daily oral placebo
Placebo for emtricitabine/tenofovir disoproxil fumarate
Hide Detailed Description
The Joint United Nations Programme on AIDS estimates that 14,000 persons are newly infected with HIV every day worldwide; one half of these infections occur in people between the ages of 15 and 24. New infections occur despite widespread awareness of the modes of HIV transmission and the protection afforded by condom use. Effective interventions for HIV prevention are urgently needed. This study will evaluate the safety and efficacy of chemoprophylaxis for HIV prevention in men who have sex with men (MSM) who are at high risk for HIV infection despite using condoms, receiving HIV counseling, and receiving treatment for STIs, particularly hepatitis B virus (HBV) infection. A daily combination dose of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) has been selected for evaluation because it has a well-established safety record in previous studies and was demonstrated to be effective for HIV prevention in primate models. These medications have long half-lives that allow daily dosing and do not have known interactions with hormonal contraception, methadone, or tuberculosis therapies.
Once on the study drug, participants will be followed for a variable length of time, starting within 4 weeks of their screening visit and lasting up to 144 weeks. All participants will be followed for at least 8 weeks after stopping study drug. Participants who are reactive to a Hepatitis B surface antigen (HBsAg) test will be followed for hepatic flares for 16 additional weeks for a total of 24 weeks after stopping study drug. If enrolled in the optional substudy of bone mineral density, fat distribution, and fasting lipids, the participant will be asked to return for one additional visit 24 weeks after stopping study drug. Participants who HIV seroconvert during their participation will also be followed until the end of the study.
All study visits will be at 4 week intervals. At study entry, high risk, HIV uninfected MSM will be randomly assigned to receive either daily FTC/TDF or placebo, in addition to standard HIV counseling, condoms, and sexually transmitted infection (STI) management. The study will closely monitor biological and behavioral safety, including careful analysis of drug resistance, kidney and liver function, and risk behavior.
At the screening visit, participants will undergo HIV antibody and HBV testing, a medical history, a medical exam, blood and urine collection, risk behavior assessment, and STI testing. At study entry, participants will be given study medication; tested for HCV; and offered the HBV vaccine, if applicable. At all study visits, there will be HIV antibody testing, pill counts, adherence checks, study medication distribution, HIV counseling, and condom distribution. A medical history and blood will be taken on selected visits, along with STI testing and treatment if needed. Testing and treatment of STIs will be provided at no cost to the participant.
All study participants will be encouraged to join a substudy that will assess interactions between HBV infection, bone mineral density and fat distribution, and immune function. If enrolled in the substudy, the participant will be asked to return for one additional visit 24 weeks after stopping the study medication. All participants in the substudy will undergo dual energy x-ray absorptiometry (DEXA) scans, and HIV infected participants will undergo additional blood collection.
Sites will have the option of participating in the following four substudies:
The Hair Substudy: Participants who are receiving FTC/TDF will be eligible to enroll. At each 12-week follow-up study visit, hair samples will be collected and questionnaires will be completed.
The Urine Substudy: For all participants who elect to enroll in this substudy, additional testing will occur on blood and urine samples collected at each 24-week follow-up visit. An additional urine collection will occur 8 weeks after participants stop receiving FTC/TDF.
The Semen Substudy: Participants who seroconvert during the study may elect to participate in this substudy. One semen sample will be collected at participants' next study visit when plasma viral load testing is performed.
The Gonorrhea and Chlamydia Substudy: Participants in this substudy will undergo rectal and oropharyngeal swab procedures and urine collection at the 24-week study visit.
After the randomized phase ends, if the daily oral FTC/TDF arm is shown to be beneficial and safe, participants will be given the option of participating in an open label extension phase. During this extension phase, study participants will receive daily oral open-label FTC/TDF, in addition to standard counseling, condoms, and STI management.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00458393
|United States, California|
|San Francisco Dept. of Public Health iPrEx CRS|
|San Francisco, California, United States, 94102|
|United States, Illinois|
|Stroger Hospital of Cook County/Core Center IPREX CRS|
|Chicago, Illinois, United States, 60612|
|United States, Massachusetts|
|Fenway Community Health iPrEx CRS|
|Boston, Massachusetts, United States, 02215|
|IPEC/FIOCRUZ iPrEx CRS|
|Rio de Janeiro, Brazil, 21040-900|
|Projeto Praca Onze, Universidade Federal do Rio de Janeiro iPrEx CRS|
|Rio de Janeiro, Brazil, 21941.590|
|Universidade de Sao Paulo iPrEx CRS|
|Sao Paulo, Brazil, 05403|
|Fundación Ecuatoriana Equidad, Guayaquil, iPrEx CRS|
|Guayaquil, Guayas, Ecuador|
|Asociación Civil Selva Amazónica, Iquitos, iPrEx CRS|
|Iquitos, Maynas, Peru|
|Investigaciones Médicas en Salud (INMENSA), Lince, iPrEx CRS|
|Desmond Tutu HIV Ctr. iPrEx CRS|
|Cape Town, South Africa, 7925|
|Research Institute for Health Sciences iPrEx CRS|
|Chiang Mai, Thailand, 50200|
|Principal Investigator:||Robert M. Grant, MD, MPH||J. David Gladstone Institutes, University of California San Francisco|